Literature DB >> 25442319

Synthesis and SAR studies of bis-chromenone derivatives for anti-proliferative activity against human cancer cells.

Eeda Venkateswararao1, Vinay K Sharma1, Manoj Manickam1, Jieun Yun2, Sang-Hun Jung3.   

Abstract

A novel family of 3-((4-oxo-4H-chromen-3-yl)methyl)-4H-chromen-4-one (bis-chromone) derivatives were designed, synthesized and studied for their anti-cancer activity using the XTT assay for the growth inhibition against various human cancer cells. Among them, 3-((5-(cyclohexylmethoxy)-4-oxo-4H-chromen-3-yl)methyl)-7-methoxy-4H-chromen-4-one and 3-((5-(cyclohexylmethoxy)-4-oxo-4H-chromen-3-yl)methyl)-7-hydroxy-4H-chromen-4-one showed micromolar level of in vitro anti-proliferative activity against human cancer cell lines. The SAR studies indicated bis-chromone as a basic scaffold to design anticancer agents. The 5-cyclohexylmethoxy on the first chromenone ring and electron donating group such as CH3, OCH3 or hydrogen bonding group (OH) on the other chromenone ring of bis-chromone increased the activity. However, saturation of one of chromenone to chromanone in bis-chromones decreased the activity.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-cancer; Bis-chromone; Cytotoxicity

Mesh:

Substances:

Year:  2014        PMID: 25442319     DOI: 10.1016/j.bmcl.2014.09.057

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Crystal structure of 3-(hy-droxy-meth-yl)chromone.

Authors:  Yoshinobu Ishikawa
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-06-20

Review 2.  Synthesis of heterocyclic analogs of isoflavone and homoisoflavone based on 3-formylchromone.

Authors:  S S Shatokhin; V A Tuskaev; S Ch Gagieva; É T Oganesyan
Journal:  Russ Chem Bull       Date:  2021-07-14       Impact factor: 1.222

3.  New chroman-4-one/thiochroman-4-one derivatives as potential anticancer agents.

Authors:  Seref Demirayak; Leyla Yurttas; Nalan Gundogdu-Karaburun; Ahmet Cagri Karaburun; Ismail Kayagil
Journal:  Saudi Pharm J       Date:  2017-04-26       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.